Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309558 | 0.74 | MAPK1 (0.38) | ALDH1A1CYP2C19MAPK1LMNAKMT2A | |
| SCHEMBL101485 | 0.74 | ALDH1A1 (0.35) | ALDH1A1CYP2C19MAPK1LMNAKMT2A | |
| SCHEMBL23189803 | 0.74 | LMNA (0.33) | ALDH1A1CYP2C19MAPK1LMNAKMT2A | |
| SCHEMBL26050836 | 0.72 | — | — | |
| SCHEMBL2796951 | 0.71 | GPR119 (0.40) | ALDH1A1CYP2C19MAPK1LMNAKMT2A | |
| SCHEMBL1059024 | 0.70 | LMNA (0.35) | ALDH1A1CYP2C19MAPK1LMNAKMT2A | |
| SCHEMBL1965395 | 0.69 | — | — | |
| SCHEMBL2376071 | 0.69 | TSHR (0.37) | MAPK1TSHRSMN1; SMN2 | |
| SCHEMBL2228600 | 0.69 | ALDH1A1 (0.40) | ALDH1A1MAPK1LMNAKMT2AMEN1 | |
| SCHEMBL25638721 | 0.68 | ESR2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4596544-A1 | EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Miracure Biotechnology Limited (CN) | 2025-08-06 | — | — | EP | disclosed |
| CN-117843618-A | EP300/CBP regulator and preparation method and application thereof | 北京沐华生物科技有限责任公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240109868-A1 | EP300/CBP MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Miracure Biotechnology Limited (CN) | 2024-04-04 | — | — | US | disclosed |
| WO-2024046504-A1 | EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京沐华生物科技有限责任公司 | 2024-03-07 | — | — | WO | disclosed |
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK (No.4) Limited (GB) | 2022-10-11 | — | — | US | disclosed |
| EP-3750910-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV Healthcare UK(No.4) Limited (GB) | 2020-12-16 | — | — | EP | disclosed |
| EP-3750910-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV Healthcare UK(No.4) Limited (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2020-11-19 | — | — | US | disclosed |
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2020-11-19 | — | — | US | disclosed |
| US-10780102-B2 | Triterpenoids with HIV maturation inhibitory activity | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-9527882-B2 | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK (No.4) Limited (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9527882-B2 | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK (No.4) Limited (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9527882-B2 | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK (No.4) Limited (GB) | 2016-12-27 | — | — | US | disclosed |
| WO-2015157483-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150291655-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-20150291655-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-20150291655-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| WO-2015157483-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-15 | — | — | WO | disclosed |
| US-8389561-B2 | Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions | UNIVERSITEIT GENT (BE) | 2013-03-05 | — | — | US | disclosed |
| US-20100093807-A1 | SUBSTITUTED 7-AZABICYCLO[2.2.1]HEPTYL DERIVATIVES USEFUL FOR MAKING PHARMACEUTICAL COMPOSITIONS | UNIVERSITEIT GENT (BE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109868-A1 | EP300/CBP MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | EP300, CREBBP, BPTF | ALDH1A1 3080/4885CYP2C19 4693/4885MAPK1 1232/4885 |
| US-10780102-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885CYP2C19 226/4885MAPK1 2233/4885 |
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885CYP2C19 226/4885MAPK1 2233/4885 |
| US-20100093807-A1 | SUBSTITUTED 7-AZABICYCLO[2.2.1]HEPTYL DERIVATIVES USEFUL FOR MAKING PHARMACEUTICAL COMPOSITIONS | CHRNA7, CHRNA5, CHRNA6 | ALDH1A1 626/4885CYP2C19 333/4885MAPK1 1748/4885 |
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885CYP2C19 226/4885MAPK1 2233/4885 |
| US-20150291655-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885CYP2C19 226/4885MAPK1 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.